Nanopath is revolutionizing the future of molecular diagnostics.
Nanopath has successfully harnessed the power of surface plasmon resonance (SPR) – the most sensitive biochemical assay on earth
Building upon decades of scientific innovation, we invented the only robust, rapid & scalable SPR biosensor that can be deployed in real-world settings.
Rapid and Sensitive
Eliminates the need for nucleic acid amplification, dramatically decreasing time-to-result.
Highly Multiplexed
Detects ten to hundreds of biomarkers simultaneously, bringing comprehensive insights to clinicians and patients.
Ultra-Low Cost
Utilizes proprietary high-throughput manufacturing capabilities for optical biosensor fabrication.
We’ve innovated across scientific disciplines to enhance diagnostic performance, speed, & ease-of-use.
We’ve packaged groundbreaking technology into a low-cost, user-friendly platform.
Nanopath’s cartridge-and-reader system provides comprehensive, lab-quality results in just 10-15 minutes at the point of care — enabling proactive, same-visit decision making.
Award-Winning Innovation
Nanopath was awarded the Disruptive Technology Award by the Association for Diagnostics & Laboratory Medicine (ADLM, formerly AACC), the premier scientific body in laboratory medicine. This annual recognition is awarded for an “innovative testing solution that will transform patient care” and speaks to the groundbreaking nature of our approach.
Nanopath is an NIH- and NSF-backed company developing state-of-the-art technology grounded in scientific rigor.
Nanopath’s platform has not yet been evaluated or cleared by the FDA.